WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

Coalition of Women Living with HIV and Aids (Cowlha) says an initiative they introduced to promote adherence to ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by. Presented ...

Six months after President Donald Trump's foreign aid cuts, millions have lost access to HIV prevention medication.

The recommendation comes just weeks after the US Food and Drug Administration (FDA) approved the drug for use. Lenacapavir trials were conducted in Uganda and South Africa and demonstrated 100% ...

PEPFAR was launched in 2003 to stop the spread of HIV in Africa. Now, although some funding remains for the program, many of ...

This isn't about managing the AIDS pandemic. It's about ending it -- and letting a new generation grow and thrive free of its threat.

A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Global HIV leaders have urged African countries to fully own their HIV responses and called on governments to urgently invest ...